Controversies and advances in the management of systemic lupus erythematosus in children and adolescents

Best Practice and Research: Clinical Rheumatology

Volumn 16, Issue 3, 2002, Pages 471-480

  Tucker, Lori B ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anti phospholipid syndrome; Paediatrics; Systemic lupus erythematosus; Therapy

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BROMOCRIPTINE; CD40 LIGAND; COMPLEMENT COMPONENT C5 MONOCLONAL ANTIBODY; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GONADORELIN DERIVATIVE; HEPARIN; HORMONE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10 MONOCLONAL ANTIBODY; LPJ 394; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG; WARFARIN; GLUCOCORTICOID; CORTICOSTEROID; PHOSPHOLIPID ANTIBODY;

ADOLESCENT; AMENORRHEA; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; BONE DENSITY; BONE MINERAL; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TOXICITY; HAIR LOSS; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LEUKOPENIA; MOON FACE; MORBIDITY; NAUSEA; NEPHRITIS; OBESITY; OSTEOPOROSIS; OUTCOMES RESEARCH; OVARY INSUFFICIENCY; PNEUMONIA; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REVIEW; SHORT STATURE; STRIA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TREATMENT FAILURE; VASCULITIS; DRUG COMBINATION; CHILDHOOD MORTALITY; CLINICAL FEATURE; LONG TERM CARE; RASH; TREATMENT OUTCOME;

ADOLESCENT; CHILD; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MORBIDITY;

EID: 0036652038     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6942(02)90254-8     Document Type: Review

References (48)

1. Cameron JS. Lupus nephritis in childhood and adolescence. Paediatric Nephrology 1994; 8: 230-249.
2. Lacks S & White P. Morbidity associated with childhood systemic lupus erythematosus. Journal of Rheumatology 1990; 17: 941-945.
3. Tucker LB, Menon S, Schaller JG & Isenberg DA. Adult and childhood onset systemic lupus erythematosus: A comparison of onset, clinical features, serology, and outcome. British Journal of Rheumatology 1995; 34: 866-872.
4. Ginzler E, Sharon E, Diamond H & Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis and Rheumatism 1975; 18: 27-34.
5. Nossent HC & Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology (Oxford) 2000; 39: 969-974.
6. Ravelli A, Ballardini G, Viola S et al. Methotrexate therapy in refractory paediatric onset systemic lupus erythematosus. Journal of Rheumatology 1988; 25: 572-575.
7. Caccavo D, Lagana B, Mitterhoffer AP et al. The long term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis and Rheumatism 1997; 40: 27-35.
8. Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations. Journal of the American Society of Nephrology 1999; 10: 833-839.
9. Li L-S, Hu W-X, Zhou H & Liu Z-H. Clinico-pathological evaluation of mycophenolate mofetil therapy in twenty-three cases of diffuse proliferative lupus nephritis. Journal of the American Society of Nephrology 1999; 10: 172.
10. Gaubitz M, Schorat A, Schotte H et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: An open pilot trial. Lupus 1999; 8: 731-736.
11. Chan TM, Li FK, Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. New England Journal of Medicine 2000; 343: 1156-1162.
12. Buratti S, Szer IS, Spencer CH et al. Mycophenolate mofetil treatment of severe renal disease in paediatric onset systemic lupus erythematosus. Journal of Rhematology 2001; 28: 2103-2108.
13. Imundo LF, Ebner-Lyon L, Li SC et al. An increased relapse rate in the second year follow-up of mycophenolate mofetil therapy in childhood SLE. Arthritis and Rheumatism 2001; 44 (supplement): S261.
14. Boumpas DT, Austin HA 3rd, Vaughan EM et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Annals of Internal Medicine 2001; 119: 366-369.
15. Onel KB, Albrecht SS & Lehman TJA. Cyclophosphamide for pediatric SLE and nephritis - Continued success. Arthritis and Rheumatism 2001; 44 (supplement): S261.
16. Lehman TJA & Onel KB. Intermittent intravenous cyclophosphamide arrests the progression of the renal chronicity index in childhood systemic lupus erythematosus. Journal of Pediatrics 2000; 136: 243-247.
17. D'Cruz D. Antimalarial therapy: A panacea for mild lupus? Lupus 2001; 10: 148-151.
18. The Canadian Hydroxychloroquine Study Group. A randomised study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. New England Journal of Medicine 1991; 324: 150-154.
19. Rahman P, Gladman DD, Urowitz MB et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with systemic lupus erythematosus. Journal of Rheumatology 1999; 26: 325-330.
20. Traynor AE, Schroeder J, Rosa RM et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study. Lancet 2000; 356: 701-707.
21. Wulffraat NM, Sanders EA, Kamphuis SS et al. Prolonged remission without treatment after autologous stem cell transplantation for refractory childhood systemic lupus erythematosus. Arthritis and Rheumatism 2001; 44: 728-731.
22. Strand V. Monoclonal antibodies and other biologic therapies. Lupus 2001; 10: 216-221.
23. Davis JC, Totoritis MC, Rosenberg J et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. Journal of Rhematology 2001; 28: 95-101.
24. Furie RA, Cash JM, Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 394. Journal of Rhematology 2001; 28: 257-265.
25. Alarcon-Segovia D, Tumlin J, Furie R et al. SLE trial shows fewer renal flares in LJP 394 treated patients with high affinity antibodies to LJP394: 90-05 trial results. Arthritis and Rheumatism 2000; 43: S272.
26. Walker SE. Bromocriptine treatment of systemic lupus erythematosus. Lupus 2001; 10: 762-768.
27. Blanco-Favela F, Quintal MAG, Chavez-Rueda AK et al. Anti-prolactin autoantibodies in paediatric systemic lupus erythematosus patients. Lupus 2001; 10: 803-808.
28. Graf AE, Salah S, Shaarawy M, Zaky S & Anwer S. Prolactin hormone in juvenile systemic erythematosus. A possible relationship to disease activity and CNS manifestation. Journal of Rheumatology 1999; 23: 374-377.
29. McMurray RW, Allen SH, Braun AL et al. Longstanding hyperprolactinemia associated with systemic lupus erythematosus: Possible hormonal stimulation of an autoimmune disease. Journal of Rheumatology 1994; 21: 843-850.
30. McMurray RW, Weidensaul D, Allen SH & Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. Journal of Rheumatology 1995; 22: 2084-2091.
31. Alvarez-Nemeguei J, Cobarrubias-Cobbs A, Escalante-Triay F et al. Bromocriptine in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled study. Lupus 1998; 7: 414-419.
32. Seaman DE, Londino V, Kwoh CK et al. Antiphospholipid antibodies in paediatric systemic lupus erythematosus. Pediatrics 1995; 96: 1040-1045.
33. Ravelli A, Caporali R, DiFuccia G et al. Anticardiolipin antibodies in paediatric systemic lupus erythematosus. Archives of Paediatric and Adolescent Medicine 1994; 148: 398-402.
34. Berube C, Mitchell L, Silverman E et al. The relationship of antiphospholipid antibodies to thromboembolic events in systemic lupus erythematosus: A cross-sectional study. Paediatric Research 1998; 44: 351-356.
35. Tuckler LB. Antiphospholipid syndrome in childhood: The great unknown. Lupus 1994; 3: 367-369.
36. Ruiz-Irastorza G, Khamashta MA & Hughes GRV. Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome. Lupus 2001; 10: 241-245.
37. Khamashta MA, Cuadrado MJ, Mujic F et al. The management of thrombosis in the antiphospholipid-antibody syndrome. New England Journal of Medicine 1995; 332: 993-997.
38. Al-Abbad AJ, Cabral DA, Sanatani S et al. Echocardiography and pulmonary function testing in childhood onset systemic lupus erythematosus. Lupus 2001; 10: 32-37.
39. Friedman DM, Lazarus HM & Fierman AH. Acute myocardial infarction in paediatric systemic lupus erythematosus. Journal of Paediatrics 2001; 117: 263-266.
40. Karrar A, Sequeira W & Block JA. Coronary artery disease in systemic lupus erythematosus: A review of the literature. Seminars in Arthritis and Rheumatism 436-443.
41. Manzi S, Meilahan EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina of women with systemic lupus erythematosus: Comparison with the Framingham Offspring Study. American Journal of Epidemiology 2001; 145: 408-415.
42. Bruce IN, Burns RJ, Gladman DD & Urowitz MB. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus and distribution of abnormalities. Journal of Rheumatology 2001; 27: 2372-2377.
43. Salmon JE & Roman MJ. Accelerated atherosclerosis in systemic lupus erythematosus: Implications for patient management. Current Opinion in Rheumatology 2001; 13: 341-344.
44. Lakshminarayanan S, Walsh S, Mohanraj M & Rothfield N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. Journal of Rheumatology 2001; 28: 102-108.
45. Trapani S, Civinni R, Ermini M et al. Osteoporosis in juvenile systemic lupus erythematosus: A longitudinal study of the effect of steroids on bone mineral density. Rheumatology International 2001; 18: 45-49.
46. Mok CC, Lau CS & Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis and Rheumatism 2001; 41: 831-837.
47. Petri M. The egg and I: Preserving fertility in systemic lupus erythematosus. Lupus 2001; 9: 399-400.
48. Blumenfeld Z, Shapiro D, Shteinberg M et al. Preservation of fertility and ovarian function and minimising gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2001; 9: 401-405.